No Data
EnVVeno Medical Highlights Successful 2024 VEITH Symposium With Launch of Recap Website
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
EnVVeno Medical To Present Data From VenoValve Trial At 51st Annual VEITH Symposium; Data Includes Showing 85% Clinical Meaningful Benefit Responder Rate, 87% Median Ulcer Area Reduction
EnVVeno Medical to Present Definitive One Year Data From the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
EnVVeno Medical Submits PMA Application To FDA To Sell And Market VenoValve In The US
EnVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval